MedTrace Logo

Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

NCT00171873 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2020-03-26

Study results available
· View outcomes & findings →

Summary

Placebo-controlled prospective randomized phase III study to investigate the antiproliferative effect of octreotide in patients with metastasized neuroendocrine tumors of the midgut

Conditions

Interventions

DRUG

Octreotide LAR (Long-acting release)

30 mg intramuscularly every 28 days

DRUG

Placebo

Sodium chloride intramuscularly every 28 days

Sponsors & Collaborators

  • Carmen Schade-Brittinger

    lead OTHER

Principal Investigators

  • Rudolf Arnold, MD, Prof · Philipps University Marburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Primary Completion
2008-06-30
Completion
2013-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00171873 on ClinicalTrials.gov